We are live on
!
Find out more
CCM
Copernicus Capital Management Portfolio holdings
AUM
$8.26M
1-Year Est. Return
37.91%
This Fund
S&P 500
This Quarter
Est. Return
+25.89%
1 Year Est. Return
+37.91%
3 Year Est. Return
+125.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.42M
AUM Growth
-$98.6M
(-94%)
Cap. Flow
-$105M
Cap. Flow
% of AUM
-1,639.98%
Top 10 Holdings %
Top 10 Hldgs %
78.79%
Holding
22
New
4
Increased
–
Reduced
11
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rocket Pharmaceuticals
RCKT
|
+$292K |
| 2 |
IGMS
IGM Biosciences
IGMS
|
+$281K |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$280K |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$267K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$13.8M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$12.4M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$12.2M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$9.61M |
| 5 |
Fate Therapeutics
FATE
|
+$9.32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BioMarin Pharmaceuticals
BMRN
$11.4B
| $940K | 14.65% |
10,719
-154,462
| -94% | -$12.2M |
|
|
2
Vertex Pharmaceuticals
VRTX
$120B
| $729K | 11.36% |
3,085
-41,904
| -93% | -$9.61M |
|
|
3
Bristol-Myers Squibb
BMY
$126B
| $703K | 10.96% |
11,327
-201,987
| -95% | -$12.4M |
|
|
4
AbbVie
ABBV
$454B
| $501K | 7.81% |
4,676
-143,763
| -97% | -$13.8M |
|
|
5
Rocket Pharmaceuticals
RCKT
$358M
| $439K | 6.84% |
+8,000
| New | +$292K |
|
6
Teladoc Health
TDOC
$1.56B
| $389K | 6.06% |
1,944
-19,556
| -91% | -$3.98M |
|
7
IQVIA
IQV
$34.6B
| $375K | 5.84% |
2,094
-37,338
| -95% | -$6.29M |
|
|
IGMS
8
DELISTED
IGM Biosciences
IGMS
| $353K | 5.5% |
+4,000
| New | +$281K |
|
|
GWPH
9
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $322K | 5.02% |
2,788
-49,700
| -95% | -$5.57M |
|
10
TG Therapeutics
TGTX
$8.5B
| $304K | 4.74% |
5,847
-89,153
| -94% | -$3.01M |
|
11
Neurocrine Biosciences
NBIX
$17.5B
| $296K | 4.61% |
3,089
-24,911
| -89% | -$2.41M |
|
|
12
Fate Therapeutics
FATE
$294M
| $295K | 4.6% |
3,240
-150,057
| -98% | -$9.32M |
|
|
ARNA
13
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $287K | 4.47% |
+3,740
| New | +$280K |
|
|
14
Alnylam Pharmaceuticals
ALNY
$35.9B
| $260K | 4.05% |
+2,000
| New | +$267K |
|
|
TBIO
15
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $223K | 3.48% |
12,091
-215,628
| -95% | -$3.86M |
|
16
Arcus Biosciences
RCUS
$3.74B
| – | – |
-171,982
| Closed | -$2.95M |
|
17
Revolution Medicines
RVMD
$40.1B
| – | – |
-81,000
| Closed | -$2.82M |
|
|
ACCD
18
DELISTED
Accolade Inc
ACCD
| – | – |
-50,000
| Closed | -$1.94M |
|
|
EIGR
19
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| – | – |
-7,938
| Closed | -$1.94M |
|
|
CBAY
20
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-278,416
| Closed | -$2.02M |
|
|
ARNA
21
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
| – | – |
-85,537
| Closed | -$6.4M |
|
|
MYOK
22
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| – | – |
-42,186
| Closed | -$5.75M |
|
Similar funds
AAM
IR
YEPV
LC
MA
IFC
PVMCV
ARTA
Copernicus Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Copernicus Capital Management held 22 positions worth $6.42M, down 94% from $105M the previous quarter. Its ten largest holdings account for 79% of the portfolio.
Copernicus Capital Management withdrew a net $105M in Q4 2020, closing 7 positions and reducing 11 holdings. Its most notable exit was MyoKardia, Inc. Common Stock, an estimated $5.75M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 92% a quarter earlier, followed by Industrials.
Against the trend, Copernicus Capital Management opened a new position in Rocket Pharmaceuticals worth $439K.
- Copernicus Capital Management's largest Q4 2020 buy was Rocket Pharmaceuticals: 8,000 shares worth $439K.
- Copernicus Capital Management's biggest Q4 2020 reduction was AbbVie, cutting an estimated $13.8M.
- Copernicus Capital Management fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $5.75M.
- Copernicus Capital Management's ten largest holdings make up 79% of its $6.42M portfolio in Q4 2020.
- Copernicus Capital Management opened 4 new positions and closed 7 in Q4 2020.
- Copernicus Capital Management's portfolio value fell 94% quarter-over-quarter to $6.42M.
Based on Copernicus Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.